HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chong Liu Selected Research

PNU-282987

11/2017Activating α7 nicotinic acetylcholine receptor inhibits NLRP3 inflammasome through regulation of β-arrestin-1.
12/2016Baroreflex deficiency aggravates atherosclerosis via α7 nicotinic acetylcholine receptor in mice.
6/2012Combined administration of anisodamine and neostigmine produces anti-shock effects: involvement of α7 nicotinic acetylcholine receptors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chong Liu Research Topics

Disease

44Neoplasms (Cancer)
07/2022 - 03/2005
13Breast Neoplasms (Breast Cancer)
01/2022 - 01/2008
11Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
11/2022 - 04/2017
11Inflammation (Inflammations)
06/2021 - 02/2011
9Infections
12/2021 - 05/2003
9Hypoxia (Hypoxemia)
01/2021 - 01/2008
8Neoplasm Metastasis (Metastasis)
01/2022 - 10/2012
7Prostatic Neoplasms (Prostate Cancer)
11/2021 - 03/2016
7Reperfusion Injury
10/2021 - 01/2018
7Hepatocellular Carcinoma (Hepatoma)
01/2021 - 10/2014
6Spinal Tuberculosis (Pott's Disease)
08/2022 - 01/2022
6Shock
09/2021 - 01/2011
5Ankylosing Spondylitis
05/2022 - 10/2020
5Glioma (Gliomas)
01/2022 - 11/2012
5Obesity
01/2022 - 01/2017
4Melanoma (Melanoma, Malignant)
01/2022 - 01/2021
4COVID-19
01/2022 - 01/2020
4Carcinoma (Carcinomatosis)
11/2021 - 10/2014
4Brain Ischemia (Cerebral Ischemia)
10/2021 - 12/2018
4Ischemic Stroke
10/2021 - 01/2019
4Osteosarcoma (Osteogenic Sarcoma)
01/2021 - 10/2015
4Atherosclerosis
01/2021 - 02/2016
4Neuroinflammatory Diseases
01/2021 - 01/2017
4Myocardial Infarction
12/2020 - 08/2013
4Pregnancy Complications
10/2020 - 03/2018
3Ewing Sarcoma (Sarcoma, Ewing)
01/2022 - 01/2021
3Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
10/2021 - 12/2018
3Tuberculosis (Tuberculoses)
01/2021 - 04/2004
3Alzheimer Disease (Alzheimer's Disease)
01/2021 - 11/2012
3Chronic Pain
01/2021 - 07/2018
3Parkinson Disease (Parkinson's Disease)
01/2021 - 10/2019
3Hypertension (High Blood Pressure)
01/2020 - 02/2011
3Intervertebral Disc Degeneration
01/2020 - 08/2016
3Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
01/2019 - 01/2016
3Temporal Lobe Epilepsy
03/2018 - 01/2013
3Septic Shock (Toxic Shock Syndrome)
10/2013 - 02/2009
3Drug Resistant Epilepsy
08/2013 - 01/2013
3Epilepsy (Aura)
05/2013 - 12/2012
2Thyroid Neoplasms (Thyroid Cancer)
10/2022 - 01/2020
2Lower Urinary Tract Symptoms
05/2022 - 09/2021
2Pain (Aches)
01/2022 - 01/2014
2Kyphosis
01/2022 - 01/2022
2Diabetic Nephropathies (Diabetic Nephropathy)
01/2022 - 01/2019
2Liver Cirrhosis (Hepatic Cirrhosis)
12/2021 - 02/2004
2Lung Neoplasms (Lung Cancer)
12/2021 - 01/2015
2Sarcoma (Soft Tissue Sarcoma)
12/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

22Biomarkers (Surrogate Marker)IBA
10/2022 - 05/2017
19Proteins (Proteins, Gene)FDA Link
07/2022 - 10/2012
8Pharmaceutical PreparationsIBA
01/2022 - 06/2012
7InflammasomesIBA
10/2021 - 12/2014
7Long Noncoding RNAIBA
02/2021 - 01/2019
7LipopolysaccharidesIBA
01/2018 - 02/2009
6AcidsIBA
10/2022 - 11/2013
6Messenger RNA (mRNA)IBA
01/2022 - 10/2012
6LigandsIBA
12/2021 - 08/2014
6Neuroprotective AgentsIBA
01/2021 - 05/2013
6Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
11/2017 - 02/2011
5anisodamineIBA
01/2022 - 01/2011
5MicroRNAs (MicroRNA)IBA
12/2021 - 01/2019
5Circular RNAIBA
11/2021 - 11/2019
5Biological ProductsIBA
10/2021 - 10/2016
5C-Reactive ProteinIBA
01/2021 - 01/2014
4Antiviral Agents (Antivirals)IBA
01/2022 - 01/2013
4Glucose (Dextrose)FDA LinkGeneric
10/2021 - 12/2018
4phthalic acid (phthalate)IBA
03/2021 - 09/2018
4Therapeutic UsesIBA
01/2021 - 11/2016
4RNA (Ribonucleic Acid)IBA
01/2021 - 01/2019
3AlbuminsIBA
08/2022 - 01/2022
3EnzymesIBA
01/2022 - 01/2019
3Interleukin-6 (Interleukin 6)IBA
01/2022 - 01/2020
3DNA (Deoxyribonucleic Acid)IBA
01/2022 - 05/2003
3ChemokinesIBA
12/2021 - 11/2020
3Oxygen (Dioxygen)IBA
10/2021 - 12/2018
3Competitive Endogenous RNAIBA
08/2021 - 01/2020
3Cadherins (E-Cadherin)IBA
02/2021 - 06/2018
3Peptides (Polypeptides)IBA
01/2020 - 10/2014
3DexmedetomidineFDA Link
12/2019 - 12/2018
3sulforaphaneIBA
01/2019 - 01/2016
3PNU-282987IBA
11/2017 - 06/2012
3AdiponectinIBA
11/2017 - 01/2017
3KetanserinIBA
12/2016 - 11/2011
3Neostigmine (Neostigmine Bromide)IBA
11/2016 - 06/2012
2ORALIT (ORS)IBA
10/2022 - 01/2020
28-Hydroxy-2'-DeoxyguanosineIBA
10/2022 - 03/2021
2AntioxidantsIBA
07/2022 - 01/2014
2CateninsIBA
05/2022 - 01/2020
2VemurafenibIBA
01/2022 - 01/2021
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 08/2014
2Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 02/2015
2Adenosine DeaminaseIBA
01/2022 - 01/2021
2InterleukinsIBA
12/2021 - 11/2011

Therapy/Procedure

23Therapeutics
01/2022 - 02/2004
6Solid-State Lasers
11/2022 - 10/2017
6Deep Brain Stimulation
01/2021 - 01/2013
4Drug Therapy (Chemotherapy)
11/2020 - 02/2015
3Immunotherapy
01/2022 - 11/2020
3Chinese Traditional Medicine (Traditional Chinese Medicine)
01/2022 - 04/2018
2Blood Transfusion (Blood Transfusions)
02/2022 - 01/2022
2Length of Stay
01/2022 - 03/2012
2Oral Administration
01/2022 - 01/2021